Virtual Colonoscopy Promising for Colon Cancer Screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

SAN DIEGO-Virtual colonoscopy is an accurate screening tool for colorectal cancer in lesions greater than 10 mm with good patient tolerance, Richard J. Farrell, MD, said at the American Gastroenterological Association meeting held during the Digestive Disease Week conference.

SAN DIEGO—Virtual colonoscopy is an accurate screening tool for colorectal cancer in lesions greater than 10 mm with good patient tolerance, Richard J. Farrell, MD, said at the American Gastroenterological Association meeting held during the Digestive Disease Week conference.

Dr. Farrell, of Beth Israel Deaconess Hospital, Boston, said that virtual colonoscopy (CT colonoscopy) employs thin-section, helical CT to generate high-resolution 2D axial images and 3D endoluminal images. The 2D image is used first, and, if a questionable lesion or polyp is observed, the image can be switched over to 3D.

In collaboration with Dr. Martina Morrin of the hospital’s radiology department, he recruited 100 patients at high risk for colorectal cancer and polyps, all around the age of 60. All underwent CT colonoscopy immediately prior to elective complete colonoscopy.

 “The patient requires no sedation with CT, unlike conventional colonoscopy, which requires conscious sedation,” Dr. Farrell said.

Using conventional colonoscopy, 45 patients had normal findings. In the other 55 patients, researchers found 88 polyps and 13 masses, including 9 carcinomas, he said.

CT colonoscopy identified 12 (90%) of the 13 masses, all of which were greater than 20 mm in diameter; 28 (92%) of 31 polyps that were greater than 10 mm in diameter; 15 (65%) of 23 that were 6 to 9 mm; and 12 (35%) of 34 that were 5 mm or smaller. There were 11 false-positive findings of polyps and three false-positive findings of masses, resulting in a specificity of 90%. The majority of false-positive tests occurred in either poorly prepped or underdistended colons.

At 0 and 24 hours, patients reported similar scores for pain and discomfort. “Patient tolerance was an important component of this study,” Dr. Farrell said. “There was no significant difference in pain, embarrassment, or discomfort, but more patients preferred the conventional colonoscopy because they preferred to be sedated.”

For CT colonoscopy to be as cost-effective as conventional colonoscopy, he said, it would need to be less than half the price of the conventional technique or need to attract considerably more patients for screening than colonoscopy.

CT colonoscopy showed excellent sensitivity and specificity for the detection of lesions 10 mm or larger in diameter, but missed one third of polyps 6 to 9 mm in diameter, he concluded. The best test, “the gold standard,” he said, remains conventional colonoscopy. “CT is a good diagnostic tool, but you can’t remove tissue, so patients with polyps prefer conventional colonoscopy.” He added that large prospective trials comparing CT with conventional colonoscopy in a screening population are required.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content